Cargando…
CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin
The implications of these findings are significant for development of CXCR2 antagonists and other mechanisms targeting neutrophil activation or NETosis, suggesting that IL-8-dependent mechanisms will only work in a subset of COPD patients https://bit.ly/32SeisO
Autores principales: | Keir, Holly R., Richardson, Hollian, Fillmore, Christina, Shoemark, Amelia, Lazaar, Aili L., Miller, Bruce E., Tal-Singer, Ruth, Chalmers, James D., Mohan, Divya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682717/ https://www.ncbi.nlm.nih.gov/pubmed/33263062 http://dx.doi.org/10.1183/23120541.00583-2020 |
Ejemplares similares
-
The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects
por: Miller, Bruce E., et al.
Publicado: (2015) -
The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers
por: Miller, Bruce E., et al.
Publicado: (2014) -
Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial
por: Mohan, Divya, et al.
Publicado: (2021) -
CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
por: Lazaar, Aili L., et al.
Publicado: (2020) -
Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD
por: Lonergan, Mike, et al.
Publicado: (2020)